This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Time To Efficacy and Onset Of Action Of Linezolid

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: September 2, 2005
Last updated: May 9, 2011
Last verified: May 2011
To assess the onset of action of linezolid

Condition Intervention Phase
Gram-Positive Bacterial Infections Skin and Connective Tissue Diseases Drug: linezolid Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time to defervescence

Secondary Outcome Measures:
  • Reduction of CRP levels Reduction of leucocyte count

Enrollment: 118
Study Start Date: June 2003
Study Completion Date: June 2005

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • suspected grampositive infection
  • fever > 38 C

Exclusion Criteria:

  • Infections to be treated successfully by surgical procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00147511

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer Identifier: NCT00147511     History of Changes
Other Study ID Numbers: OXAA-0026-162
Study First Received: September 2, 2005
Last Updated: May 9, 2011

Additional relevant MeSH terms:
Bacterial Infections
Connective Tissue Diseases
Gram-Positive Bacterial Infections
Anti-Bacterial Agents
Anti-Infective Agents
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017